Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | FHIT | P49789 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11945539 | 0.86 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL25078375 | 0.86 | CYP2C9 (0.68) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL391859 | 0.84 | KMT2A (0.67) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL1550557 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL15440699 | 0.84 | KMT2A (0.73) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL1750835 | 0.83 | KMT2A (0.77) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2538523 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL28748456 | 0.82 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2546655 | 0.81 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL25077819 | 0.81 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024172631-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | 주식회사 카나프테라퓨틱스 | 2024-08-22 | — | — | WO | disclosed |
| CN-118119600-A | SOS1 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| US-10479771-B2 | Pyridazinone and pyridone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2019-11-19 | — | — | US | disclosed |
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2018-02-01 | — | — | US | disclosed |
| US-9815795-B2 | Pyridazinone and pyridone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2017-11-14 | — | — | US | disclosed |
| EP-2683711-B1 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORP (FI) | 2017-02-01 | — | — | EP | disclosed |
| US-20160244414-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2016-08-25 | — | — | US | disclosed |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-2010165-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007127711-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | ALDH1A1 3297/4885SMN1; SMN2 4837/4885CYP2C9 539/4885 |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1723/4885SMN1; SMN2 3954/4885CYP2C9 144/4885 |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | NRAS, BRAF, MAPK9 | ALDH1A1 1962/4885SMN1; SMN2 3942/4885CYP2C9 139/4885 |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | ALDH1A1 1380/4885SMN1; SMN2 3932/4885CYP2C9 178/4885 |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1991/4885SMN1; SMN2 4172/4885CYP2C9 130/4885 |
| US-20160244414-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | ALDH1A1 259/4885SMN1; SMN2 3199/4885CYP2C9 54/4885 |
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | ALDH1A1 259/4885SMN1; SMN2 3199/4885CYP2C9 54/4885 |
| US-10479771-B2 | Pyridazinone and pyridone compounds | XDH, PNPO, PDXK | ALDH1A1 259/4885SMN1; SMN2 3199/4885CYP2C9 54/4885 |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, MAPK9 | ALDH1A1 2027/4885SMN1; SMN2 4064/4885CYP2C9 134/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1992/4885SMN1; SMN2 4055/4885CYP2C9 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.